Skip to main content

Improving Comprehension of Graft-Versus-Host-Disease for Enhanced Patient Outcomes

Recently, i3 Health provided an educational activity that challenged knowledge gaps experienced by clinicians regarding improved patient outcomes in graft-versus-host disease (GVHD).   Graft-versus-host disease is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality. Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver. Chronic GVHD often presents within t...

Continue reading

Practice-Changing Proficiency for the Management of Marginal Zone Lymphoma

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding new clinical perspectives in the management of marginal zone lymphoma (MZL).   Marginal zone lymphoma comprises approximately 7% of all mature non-Hodgkin lymphomas (NHLs). According to the Leukemia and Lymphoma Society®, there are three subtypes: extranodal MZL, also referred to as mucosa-associated lymphatic tissue (MALT) lymphoma; splenic MZL, which originates from ...

Continue reading

Significant Knowledge Gains for the Diagnosis and Management of T-Cell Lymphoma

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding the diagnosis and evidence-based management of T-cell lymphoma (TCL). T-cell lymphoma is an uncommon subtype accounting for approximately 7% of all cases of non-Hodgkin lymphoma in the United States. Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL ...

Continue reading

Improved Understanding of Precision Medicine in BRAF V600E–Mutant Metastatic Colorectal Cancer

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding precision medicine in BRAF V600E­–mutant metastatic colorectal cancer (CRC).   Colorectal cancer is the second leading cause of cancer death among men and women in the United States, with the American Cancer Society estimating that there will be 106,970 new cases of colon cancer, 46,050 new cases of rectal cancer, and 52,550 deaths due to colorectal cancer in 2023 alon...

Continue reading

Addressing Knowledge Gaps in Management of Tumor Lysis Syndrome

Recently, i3 Health provided a continuing medical education/nursing continuing professional development/continuing pharmacy education (CME/NCPD/CPE)–approved activity, Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies, during which clinicians' knowledge gaps were challenged and knowledge gains were achieved. Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor c...

Continue reading

Overcoming Knowledge Gaps in Thyroid Cancer Management

i3 Health has provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding management and novel treatment options for differentiated and anaplastic thyroid cancer. Thyroid cancer is one of the most prevalent cancers in the United States. The American Cancer Society estimates 43,720 new cases and 2,120 deaths from the disease in the United States over the course of 2023. Thyroid cancer is typically more aggressive in men than in women and becomes increas...

Continue reading

Bridging Knowledge Gaps for Treatment of Immune Thrombocytopenia

i3 Health has provided an educational activity that has challenged knowledge gaps experienced by nursing staff regarding updated treatment options and optimal patient care for immune thrombocytopenia (ITP). ITP is an autoimmune platelet disorder in which the blood does not clot normally as a result of a low platelet count, causing bruising and bleeding. Research has shown that the burden of ITP is significant; in a survey of more than 1,300 patients from 13 different countries, 36% reported a hi...

Continue reading

Significant Knowledge Gains Acquired for Treating Metastatic Breast Cancer

An educational enduring online activity provided by i3 Health has provided knowledge gains pertaining to enhancing treatment tolerability, adherence, and patient-centered care for metastatic breast cancer. In the United States, breast cancer accounts for approximately 30% of cancer diagnoses among women and is the second-leading cause of cancer death. The American Cancer Society has estimated that in 2022 there will be 287,580 new cases of invasive breast cancer, with 43,250 of these cases resul...

Continue reading

Knowledge Gained for Treatment of Metastatic Hormone-Sensitive Prostate Cancer

An educational activity provided by i3 Health has produced knowledge gains and expertise regarding the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In the United States, prostate cancer is the most common tumor type affecting men. The American Cancer Society estimated for 2022 that there will be 268,490 new cases diagnosed, with 34,500 of these cases resulting in death. Most patients with mHSPC present with relapse after local treatment, while approximately 5% of all p...

Continue reading

Increasing Expertise for Treatment of Non-Hodgkin Lymphoma

An educational activity provided by i3 Health has bridged knowledge gaps experienced by nursing professionals and other health care professionals on the topic of treatment strategies for patients with non-Hodgkin lymphoma (NHL). Accounting for 4% of all cancers diagnosed, NHL is one of the most common cancer types in the United States. The American Cancer Society estimated that 80,470 new diagnoses of NHL will occur in 2022, with 20,250 resulting in death. Aggressive subtypes, including diffuse ...

Continue reading

Addressing Knowledge Gaps in Treatment Strategies for Cholangiocarcinoma

An educational activity provided by i3 Health has addressed knowledge gaps and produced expertise pertaining to treatment strategies for cholangiocarcinoma. Cholangiocarcinoma, also known as bile duct cancer, is a rare malignancy originating in the epithelium of the bile duct. The American Cancer Society estimates that 8,000 cases of bile duct cancer are diagnosed each year, but it is acknowledged that this number could be higher due to the cancer being hard to diagnose and the potential for mis...

Continue reading